华兰生物：公司研发的重组 Exendin-4-FC 融合蛋白注射液临床研究进展顺利

Core Viewpoint - The company, Hualan Biological, has successfully completed Phase I/II clinical trials for its recombinant Exendin-4-FC fusion protein injection, a treatment for type 2 diabetes, and is preparing to initiate Phase III trials [2] Group 1 - The company has obtained complete efficacy and safety data from the completed clinical trials [2] - Hualan Biological is applying for a new indication for overweight/obesity and has communicated with the National Medical Products Administration, which has accepted the registration application [2]